📰 Therapy Evaluation Program News
Page 2 - Therapy Evaluation Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Therapy Evaluation Program. Real-time updates on events, politics, business and more.
August 4, 2022
04.08.2022 - – Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with ...
July 6, 2022
Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or...
December 17, 2021
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...
December 17, 2021
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and...
August 19, 2021
/PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel...
March 16, 2021
Share this article Share this article LEXINGTON, Mass., March 16, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2020. "2020 was a transformative year for Curis, as we made significant progress in our mission to develop the next generation of targeted cancer therapies that meaningfully improve and ex...